MNG596
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.562
- IL6_JAK_STAT3_SIGNALING+0.557
- INTERFERON_ALPHA_RESPONSE+0.546
- ALLOGRAFT_REJECTION+0.541
- INFLAMMATORY_RESPONSE+0.445
- PI3K_AKT_MTOR_SIGNALING+0.395
- MYC_TARGETS_V1+0.384
- PROTEIN_SECRETION+0.315
- COMPLEMENT+0.305
- UNFOLDED_PROTEIN_RESPONSE+0.305
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.467
- KRAS_SIGNALING_DN-0.328
- MYOGENESIS-0.235
- SPERMATOGENESIS-0.207
- HEDGEHOG_SIGNALING-0.199
- ESTROGEN_RESPONSE_LATE-0.187
- OXIDATIVE_PHOSPHORYLATION-0.160
- CHOLESTEROL_HOMEOSTASIS-0.121
- APICAL_SURFACE-0.082
- GLYCOLYSIS-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG181 | — | — | 0.900 |
| 2 | SRR934940 | — | — | 0.894 |
| 3 | TCGA-55-8205-01A-11R-2241-07 | — | cohortA1 | 0.892 |
| 4 | SRR934942 | — | — | 0.889 |
| 5 | SRR934802 | — | — | 0.887 |
| 6 | TCGA-BT-A20O-01A-21R-A14Y-07 | — | — | 0.886 |
| 7 | SRR934830 | — | — | 0.873 |
| 8 | B4E10042-052D-4DC4-BC94-FF1D5D4632C0 | — | — | 0.872 |
| 9 | SRR934895 | — | — | 0.867 |
| 10 | 738B9C39-A73F-4BD5-A8D4-3F75B9E14569 | — | — | 0.863 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.562 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.557 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.546 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.541 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.445 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.395 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.384 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.315 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.305 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.305 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.304 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.293 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.277 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.277 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.274 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.271 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.245 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.237 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.229 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.227 | Inavolisib | — uncovered |